Experimental drug combo targets Hard-to-Treat head and neck cancer
NCT ID NCT07686588
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and an immune checkpoint inhibitor—in people with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after standard therapy. The goal is to see if the combination can shrink tumors and control the disease. About 20 participants will receive the drugs by infusion every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan plus an immune checkpoint inhibitor
- What this could lead to
- If successful, this combination could offer a new treatment option for people with head and neck cancer that has not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New chemo combo shows promise for tough head and neck cancers
- Drug combo shows promise for tough head and neck cancers
- Supercharged immune cells take on Hard-to-Treat head and neck cancer
- New drug combo shows promise for Tough-to-Treat head and neck cancer
- New vaccine combo aims to control advanced head and neck cancer
- Ultrasound boosts cancer drug in tiny trial